Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07102342 · ClinicalTrials.gov registry record · Phase 1

This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.

A Phase 1 study of Parkinson Disease, sponsored by iRegene Therapeutics Co..

Recruiting
Registry status
Phase 1
Development phase
5
Enrollment target
1
Study location

NCT07102342 is a Phase 1 study of Parkinson Disease that is actively recruiting participants, run by iRegene Therapeutics Co.. The registered enrollment target is 5 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07102342, a Phase 1 study of Parkinson Disease, is actively recruiting participants, sponsored by iRegene Therapeutics Co..

RECRUITING
Registry status
Phase 1
Development phase
5 participants
Enrollment target
1
Study location

Study Summary

This is a phase 1 clinical study to evaluate the safety, tolerability, feasibility, and preliminary efficacy of NouvNeu001 in patients with advanced Parkinson's Disease.

Conditions Studied

Parkinson Disease

Interventions

  • BIOLOGICAL Human Dopaminergic Progenitor Cells

Study Locations (1)

New York

  • Cornell University Weill Medical College - New York

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2026-01-12
Est. Completion 2032-09
Phase Phase 1

Sponsor

iRegene Therapeutics Co.

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07102342

The ClinicalTrials.gov registry entry for NCT07102342 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (100% lower). The listed sponsor is iRegene Therapeutics Co., which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which Human Dopaminergic Progenitor Cells is the first listed.

NCT07102342 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT07102342 about?

NCT07102342 is a clinical study titled "This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.". This is a phase 1 clinical study to evaluate the safety, tolerability, feasibility, and preliminary efficacy of NouvNeu001 in patients with advanced Parkinson's Disease.

What is the current status of trial NCT07102342?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2026-01-12. Estimated completion is 2032-09.

What conditions does trial NCT07102342 study?

This clinical trial studies the following conditions: Parkinson Disease.

What interventions are being tested in trial NCT07102342?

The interventions under investigation include: Human Dopaminergic Progenitor Cells (BIOLOGICAL).

Who is sponsoring clinical trial NCT07102342?

This trial is sponsored by iRegene Therapeutics Co., which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07102342 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Parkinson Disease

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.